Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402731 | 0.78 | DRD4 (0.54) | DRD4TRPV1HSD11B1AOC3 | |
| SCHEMBL3436405 | 0.77 | TRPV1 (0.50) | DRD4TRPV1HSD11B1F13A1TGM2 | |
| SCHEMBL5178342 | 0.76 | HSD11B1 (0.56) | TRPV1HSD11B1CHIA | |
| SCHEMBL18228586 | 0.76 | HSD11B1 (0.55) | DRD4TRPV1HSD11B1 | |
| SCHEMBL11962834 | 0.76 | HSD11B1 (0.55) | DRD4TRPV1HSD11B1 | |
| SCHEMBL15966094 | 0.76 | HSD11B1 (0.55) | DRD4TRPV1HSD11B1 | |
| SCHEMBL3550856 | 0.75 | HTR7 (0.51) | — | |
| SCHEMBL3436628 | 0.75 | HSD11B1 (0.49) | DRD4TRPV1HSD11B1 | |
| SCHEMBL2614921 | 0.74 | CYP1A2 (0.56) | TRPV1HSD11B1 | |
| SCHEMBL3559294 | 0.73 | HTR1A (0.37) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | DRD4 4535/4885TRPV1 3/4885HSD11B1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.